Could probiotics soothe chemo belly? new trial hopes so
NCT ID NCT07605728
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a probiotic supplement can help reduce diarrhea and belly discomfort in breast cancer patients taking the drug Abemaciclib. About 80 participants will get either the supplement or a placebo for two months, while also using standard anti-diarrhea medicine. Researchers will track symptom severity and check blood for metabolic changes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Synbiotic supplement (Bifidobacterium longum, Oligonol® lychee polyphenol, and postbiotics)
- What this could lead to
- If it works, this could offer a simple, natural way to reduce gut side effects from a common breast cancer drug, improving quality of life during treatment.
- What could go wrong
- This is a small, early-phase study (80 people) testing a dietary supplement, not a drug. The effect may be modest or no better than placebo, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: A. Adults with hormone receptor-positive (HR+) early breast cancer were confirmed. B. At least 18 years old at the time of signing the informed consent. C. Candidates for adjuvant endocrine therapy in combination with Abemaciclib (either NHI-reimbursed or self-funded), as determined by the primary treating physician. Prior chemotherapy requirement: Must have completed prior adjuvant chemotherapy at least 21 days before enrollment. All chemotherapy-related toxicities (except alopecia or Grade 2 peripheral neuropathy) must have resolved to ≤ Grade 1. D. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. E. Adequate bone marrow function as defined by: 1. Absolute Neutrophil Count (ANC) ≥ 1,500/μL without G-CSF support within 14 days of enrollment. 2. Platelet count ≥ 100,000/μL. 3. Hemoglobin ≥ 8.0 g/dL (red blood cell transfusion is permitted prior to enrollment). F. Adequate hepatic function, as defined by: 1. Serum alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤ 3× the upper limit of normal. 2. Total bilirubin (T-bil) ≤ 1.5× the upper limit of normal. G. Willingness to refrain from using any other oral probiotics or prebiotics from the first dose of the study intervention ("Synbiotic Supplement" or placebo) through study completion. H. Ability to communicate with study personnel and willingness to comply with study visits, treatment plans, and other trial regulations. Exclusion Criteria: A. Currently pregnant or breastfeeding. B. Received systemic antibiotic therapy for active viral, bacterial, or fungal infections within 2 weeks before the first dose of the study intervention. C. Severe pre-existing medical conditions that, in the investigator's judgment, preclude participation, including but not limited to the following: 1. Severe renal impairment (e.g., estimated creatinine clearance \< 30 mL/min). 2. Interstitial lung disease. 3. Severe dyspnea at rest or the requirement for oxygen therapy. 4. History of major gastrointestinal surgeries, such as gastrectomy or small bowel resection. 5. Pre-existing Crohn's disease, ulcerative colitis, or other chronic conditions that cause clinically significant diarrhea. D. History of the following cardiovascular conditions: syncope of cardiovascular origin, ventricular arrhythmias of pathological origin (including ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: Patients with atrial fibrillation that is controlled and stable for at least 30 days before randomization are eligible. E. Unwillingness or inability to provide written informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?